Total Payments
$676,040
2024 Payments
$313.72
Companies
21
Transactions
129
Medicare Patients
2,513
Medicare Billing
$355,582
Payment Breakdown by Category
Education$446,428 (66.0%)
Consulting$126,065 (18.6%)
Research$64,787 (9.6%)
Other$25,850 (3.8%)
Travel$8,338 (1.2%)
Food & Beverage$4,572 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Education | $446,428 | 6 | 66.0% |
| Consulting Fee | $126,065 | 7 | 18.6% |
| Unspecified | $64,787 | 6 | 9.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $17,375 | 2 | 2.6% |
| Travel and Lodging | $8,338 | 16 | 1.2% |
| Food and Beverage | $4,572 | 85 | 0.7% |
| Grant | $4,390 | 2 | 0.6% |
| Entertainment | $3,585 | 4 | 0.5% |
| Honoraria | $500.00 | 1 | 0.1% |
Payments by Type
General
$611,253
123 transactions
Research
$64,787
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| BIONESS INC | $556,614 | 7 | $0 (2021) |
| Eli Lilly and Company | $64,825 | 7 | $0 (2023) |
| Boston Scientific Corporation | $30,706 | 28 | $0 (2019) |
| Biogen, Inc. | $12,288 | 13 | $0 (2020) |
| Medtronic, Inc. | $4,199 | 10 | $0 (2024) |
| Medtronic USA, Inc. | $3,602 | 28 | $0 (2020) |
| PFIZER INC. | $1,560 | 3 | $0 (2017) |
| TerSera Therapeutics LLC | $465.68 | 7 | $0 (2020) |
| Saluda Medical Americas, Inc. | $375.95 | 1 | $0 (2023) |
| Nevro Corp. | $350.23 | 8 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $313.72 | 6 | Medtronic, Inc. ($192.13) |
| 2023 | $1,789 | 5 | Eli Lilly and Company ($1,253) |
| 2022 | $15,615 | 5 | Eli Lilly and Company ($15,533) |
| 2021 | $205,680 | 13 | BIONESS INC ($153,313) |
| 2020 | $144,380 | 6 | BIONESS INC ($141,936) |
| 2019 | $196,407 | 47 | BIONESS INC ($153,681) |
| 2018 | $109,509 | 28 | BIONESS INC ($107,684) |
| 2017 | $2,345 | 19 | PFIZER INC. ($1,560) |
All Payment Transactions
129 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/22/2024 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $26.44 | General |
| 09/18/2024 | Medtronic, Inc. | SYNCHROMEDII (Device) | Food and Beverage | In-kind items and services | $21.91 | General |
| Category: Drug Infusion Systems | ||||||
| 08/26/2024 | Medtronic, Inc. | INTELLIS ADAPTIVESTIM (Device) | Food and Beverage | In-kind items and services | $31.03 | General |
| Category: Spinal Cord Neurostimulation | ||||||
| 07/24/2024 | Medtronic, Inc. | SYNCHROMEDII (Device) | Food and Beverage | In-kind items and services | $139.19 | General |
| Category: Drug Infusion Systems | ||||||
| 06/14/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $21.84 | General |
| Category: Neurology | ||||||
| 02/03/2024 | SPR Therapeutics, Inc | SPRINT PNS System (Device) | Food and Beverage | Cash or cash equivalent | $73.31 | General |
| Category: Pain management | ||||||
| 05/09/2023 | Saluda Medical Americas, Inc. | Evoke SCS (Device) | Travel and Lodging | In-kind items and services | $375.95 | General |
| Category: Spinal Cord Stimulation | ||||||
| 03/08/2023 | Eli Lilly and Company | — | — | In-kind items and services | $952.85 | Research |
| Study: A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | ||||||
| 02/03/2023 | SPINAL ELEMENTS, INC. | — | Food and Beverage | Cash or cash equivalent | $48.51 | General |
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $300.00 | Research |
| Study: A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | ||||||
| 01/12/2023 | Medtronic, Inc. | INTELLIS ADAPTIVESTIM (Device) | Food and Beverage | In-kind items and services | $111.99 | General |
| Category: Spinal Cord Neurostimulation | ||||||
| 08/20/2022 | Neuronetics, Inc. | NEUROSTAR TMS THERAPY SYSTEM (Device) | Food and Beverage | Cash or cash equivalent | $41.06 | General |
| Category: NEUROSTAR TMS THERAPY SYSTEM | ||||||
| 08/20/2022 | Neuronetics, Inc. | NEUROSTAR TMS THERAPY SYSTEM (Device) | Food and Beverage | Cash or cash equivalent | $41.06 | General |
| Category: NEUROSTAR TMS THERAPY SYSTEM | ||||||
| 06/27/2022 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $38.59 | General |
| 02/01/2022 | Eli Lilly and Company | — | — | In-kind items and services | $6,882.00 | Research |
| Study: A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | ||||||
| 01/21/2022 | Eli Lilly and Company | — | — | In-kind items and services | $8,612.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 11/16/2021 | Medtronic, Inc. | ASCENDA (Device) | Food and Beverage | In-kind items and services | $24.74 | General |
| Category: Drug Infusion Systems | ||||||
| 08/28/2021 | Neuronetics, Inc. | NEUROSTAR TMS THERAPY (Device) | Food and Beverage | Cash or cash equivalent | $74.00 | General |
| Category: NEUROSTAR TMS THERAPY | ||||||
| 08/28/2021 | Neuronetics, Inc. | NEUROSTAR TMS THERAPY (Device) | Food and Beverage | Cash or cash equivalent | $31.40 | General |
| Category: NEUROSTAR TMS THERAPY | ||||||
| 08/12/2021 | Neuronetics, Inc. | NEUROSTAR TMS THERAPY (Device) | Food and Beverage | Cash or cash equivalent | $151.79 | General |
| Category: NEUROSTAR TMS THERAPY | ||||||
| 07/20/2021 | Eli Lilly and Company | — | — | Cash or cash equivalent | $40,486.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 05/04/2021 | Bioventus LLC | Stimrouter Implantable Kit (Device) | Food and Beverage | In-kind items and services | $63.75 | General |
| Category: Podiatry | ||||||
| 05/03/2021 | Medtronic, Inc. | SYNCHROMED (Device) | Food and Beverage | In-kind items and services | $9.24 | General |
| Category: Drug Infusion Systems | ||||||
| 04/14/2021 | Bioventus LLC | Stimrouter Implantable Kit (Device) | Food and Beverage | In-kind items and services | $137.07 | General |
| Category: Podiatry | ||||||
| 04/12/2021 | Eli Lilly and Company | — | — | In-kind items and services | $7,553.85 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $56,652 | 3 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $6,882 | 1 |
| A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | Eli Lilly and Company | $952.85 | 1 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $300.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 408 | 558 | $126,743 | $55,684 |
| 2022 | 4 | 607 | 1,339 | $290,045 | $93,563 |
| 2021 | 12 | 1,290 | 1,894 | $451,695 | $172,724 |
| 2020 | 5 | 208 | 278 | $74,040 | $33,611 |
Total Patients
2,513
Total Services
4,069
Medicare Billing
$355,582
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3490 | Unclassified drugs | Office | 2023 | 64 | 114 | $33,187 | $25,029 | 75.4% |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2023 | 39 | 49 | $19,600 | $11,857 | 60.5% |
| G3002 | Chronic pain management and treatment, monthly bundle including, diagnosis; assessment and monitoring; administration of a validated pain rating scale or tool; the development, implementation, revision, and/or maintenance of a person-centered care plan tha | Office | 2023 | 55 | 62 | $13,856 | $3,635 | 26.2% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2023 | 46 | 57 | $7,125 | $3,471 | 48.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 29 | 33 | $8,250 | $3,187 | 38.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 44 | 67 | $11,725 | $2,489 | 21.2% |
| 62370 | Electronic analysis reprogramming and refill of spinal canal drug infusion pump by physician | Facility | 2023 | 53 | 82 | $16,400 | $2,388 | 14.6% |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | Office | 2023 | 14 | 22 | $5,500 | $1,617 | 29.4% |
| 76942 | Ultrasonic guidance for needle placement | Facility | 2023 | 40 | 47 | $5,875 | $1,024 | 17.4% |
| 76942 | Ultrasonic guidance for needle placement | Office | 2023 | 12 | 13 | $1,625 | $579.22 | 35.6% |
| 61070 | Aspiration of cerebrospinal fluid and injection in shunt tubing or reservoir | Facility | 2023 | 12 | 12 | $3,600 | $408.07 | 11.3% |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | Office | 2022 | 325 | 733 | $182,500 | $54,501 | 29.9% |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2022 | 54 | 78 | $30,900 | $18,682 | 60.5% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2022 | 174 | 450 | $67,000 | $15,680 | 23.4% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2022 | 54 | 78 | $9,645 | $4,700 | 48.7% |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | Office | 2021 | 420 | 733 | $183,125 | $54,975 | 30.0% |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2021 | 125 | 151 | $60,400 | $37,285 | 61.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 222 | 330 | $82,725 | $35,966 | 43.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 219 | 331 | $57,925 | $22,348 | 38.6% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2021 | 124 | 148 | $18,500 | $9,197 | 49.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 31 | 31 | $14,725 | $4,123 | 28.0% |
| 62362 | Implantation or replacement of programmable spinal canal drug infusion pump | Facility | 2021 | 15 | 15 | $15,000 | $3,684 | 24.6% |
| 87426 | Elisa detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2021 | 60 | 76 | $7,600 | $2,685 | 35.3% |
| J3490 | Unclassified drugs | Office | 2021 | 16 | 16 | $1,370 | $1,086 | 79.2% |
| 61070 | Aspiration or injection of cerebrospinal fluid shunt tubing or reservoir | Facility | 2021 | 21 | 23 | $6,900 | $702.96 | 10.2% |
About Dr. Eric Grigsby, M.D
Dr. Eric Grigsby, M.D is a Pain Medicine healthcare provider based in Napa, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1952328494.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Grigsby, M.D has received a total of $676,040 in payments from pharmaceutical and medical device companies, with $313.72 received in 2024. These payments were reported across 129 transactions from 21 companies. The most common payment nature is "Education" ($446,428).
As a Medicare-enrolled provider, Grigsby has provided services to 2,513 Medicare beneficiaries, totaling 4,069 services with total Medicare billing of $355,582. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Pain Medicine
- Location Napa, CA
- Active Since 07/17/2006
- Last Updated 09/21/2011
- Taxonomy Code 208VP0000X
- Entity Type Individual
- NPI Number 1952328494
Products in Payments
- StimRouter for pain (Device) $260,997
- Stimrouter for pain (Device) $153,681
- Stimrouter for Pain (Device) $141,936
- SPECTRA WAVEWRITER (Device) $28,890
- SPINRAZA (Biological) $7,898
- AUTOFILL (Device) $2,168
- GENERAL THERAPIES (Device) $1,746
- RESTORE (Device) $668.23
- SYNCHROMED (Device) $469.42
- PRIALT (Drug) $430.26
- Evoke SCS (Device) $375.95
- Senza Spinal Cord Stimulation System (Device) $350.23
- NEUROSTAR TMS THERAPY (Device) $257.19
- Stimrouter Implantable Kit (Device) $200.82
- SYNCHROMEDII (Device) $161.10
- INTELLIS ADAPTIVESTIM (Device) $143.02
- Prialt (Drug) $123.00
- TARGETSTIM (Device) $114.90
- ADAPTIVESTIM (Device) $103.67
- SCS IPGs (Device) $99.01
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.